Volume 28, No 4, Apr 2018

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 28 Issue 4, April 2018: 433-447   |  Open Access

ORIGINAL ARTICLES

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice

Xuexiang Du ¹, Mingyue Liu ¹, Juanjuan Su ¹, Peng Zhang ¹, Fei Tang ¹, Peiying Ye ¹, Martin Devenport ², Xu Wang ¹, Yan Zhang ¹, Yang Liu ^1,2 and Pan Zheng ^1,2

¹ Center for Cancer and Immunology Research, Children’s Research Institute, Children’s National Health System, Washington, DC 20010, USA and ² OncoImmune, Inc., Rockville, MD 20852, USA Correspondence: Yang Liu (yaliu@cnmc.org) or Pan Zheng (pzheng@cnmc.org)Xuexiang Du and Mingyue Liu contributed equally to this work.

10.1038/s41422-018-0012-z

FULL TEXT | PDF

Browse 1372